Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears

Detailed summary

Intellia Therapeutics (NASDAQ:NTLA) presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the company awaits a U.S. regulatory decision. The Food and Drug Administration has accepted Intellia’s bio